Edwards Lifesciences (EW) Stock Forecast & Price Target

$89.13 -2.66 (-2.90%)

As of 09:41 AM Eastern

Compare

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
0

Hold
8

Buy
18

Based on 26 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 8 have given a hold rating, 16 have given a buy rating, and 2 have given a strong buy rating for EW.

Consensus Price Target

$97.52
9.41% Upside

According to the 26 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $97.52. The highest price target for EW is $110.00, while the lowest price target for EW is $81.00. The average price target represents a forecasted upside of 9.41% from the current price of $89.13.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for EW and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EW Analyst Ratings Over Time

Type	Current Forecast 7/14/25 to 7/14/26	1 Month Ago 6/14/25 to 6/14/26	3 Months Ago 4/15/25 to 4/15/26	1 Year Ago 7/14/24 to 7/14/25
Strong Buy	2 Strong Buy rating(s)	3 Strong Buy rating(s)	3 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	16 Buy rating(s)	16 Buy rating(s)	16 Buy rating(s)	10 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	9 Hold rating(s)	12 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$97.52	$95.96	$95.74	$80.40
Forecasted Upside	9.41% Upside	12.87% Upside	22.49% Upside	2.62% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

EW Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EW Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Edwards Lifesciences Stock vs. The Competition

Type	Edwards Lifesciences	Medical Companies	Broader Market
Consensus Rating Score	2.77	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	6.25% Upside	722.03% Upside	13.78% Upside
News Sentiment Rating	Positive News See Recent EW News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/13/2026	Royal Bank Of Canada 3 of 5 stars	Shagun Singh 3 of 5 stars	Boost Target	Outperform	$100.00 ➝ $110.00	+19.09%
7/8/2026	Citigroup 4 of 5 stars	Joanne Wuensch 2 of 5 stars	Boost Target	Buy	$101.00 ➝ $110.00	+16.05%
7/6/2026	Evercore 3 of 5 stars	Vijay Kumar 3 of 5 stars	Reiterated Rating	Outperform	$100.00	+7.66%
6/30/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marie Thibault Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$100.00 ➝ $110.00	+20.44%
6/2/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Jennings Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$97.00 ➝ $104.00	+20.47%
4/27/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$104.00 ➝ $110.00	+30.64%
4/24/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Hold	$89.00 ➝ $90.00	+8.03%
4/24/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Plovanic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Hold	$87.00 ➝ $85.00	+2.10%
4/24/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Rescott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$85.00 ➝ $87.00	+9.17%
4/20/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold (C)
ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I. (Ad) Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it. See Jeff Brown and Marc Chaikin's full analysis and next steps here
4/13/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Outperform	$100.00 ➝ $95.00	+22.95%
4/1/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Peer Perform ➝ Outperform	$92.00	+14.91%
2/11/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$108.00 ➝ $95.00	+23.38%
2/11/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$98.00 ➝ $100.00	+29.87%
2/11/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$96.00 ➝ $100.00	+31.67%
2/4/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$94.00	+14.94%
1/20/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$105.00 ➝ $110.00	+30.35%
12/18/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$90.00 ➝ $100.00	+17.85%
11/3/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lee Hambright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform	$90.00	+9.12%
11/3/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$96.00	+16.39%
10/31/2025	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$92.00	+11.54%
10/29/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Hold ➝ Buy	$80.00 ➝ $98.00	+19.14%
10/8/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Suraj Kalia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
7/29/2025	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
7/25/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
7/25/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Pito Chickering Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$85.00 ➝ $94.00	+24.21%
7/15/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$75.00 ➝ $81.00	+3.39%
7/10/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christine Dooley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
6/2/2025	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	N. Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
12/16/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$82.00 ➝ $90.00	+20.97%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:36 AM ET.

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, July 9, 2026. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com.

Edwards Lifesciences
Bull Case

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

The company reported earnings per share of $0.78 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
Edwards Lifesciences Co. achieved a revenue of $1.65 billion during the quarter, reflecting a year-over-year increase of 16.7%, showcasing its ability to grow in a competitive market.
With a net margin of 17.39%, the company demonstrates effective cost management and profitability, which can lead to higher returns for investors.
Analysts have a consensus rating of "Moderate Buy" for the stock, with a target price around $96.39, suggesting potential upside for investors considering entry points.
The current stock price is approximately $86, which may present a buying opportunity for investors looking to capitalize on the company's growth trajectory.

Edwards Lifesciences
Bear Case

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

Despite strong earnings, the stock has seen insider selling, with significant shares sold recently, which could indicate a lack of confidence from those closest to the company.
While the company has a solid return on equity of 15.19%, it may not be as competitive compared to other firms in the medical technology sector, which could limit its attractiveness to investors.
Analysts have mixed ratings, with eight assigning a Hold rating, suggesting that some investors may be cautious about the stock's future performance.
The company operates in a highly regulated industry, which can lead to uncertainties and potential delays in product approvals, impacting growth prospects.
Market volatility and economic conditions can affect the healthcare sector, and any downturn could negatively impact Edwards Lifesciences Co.'s stock performance.

EW Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $97.52, with a high forecast of $110.00 and a low forecast of $81.00.

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 8 hold ratings, 16 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EW shares.

According to analysts, Edwards Lifesciences's stock has a predicted upside of 9.41% based on their 12-month stock forecasts.

Edwards Lifesciences has been rated by research analysts at Barclays, BTIG Research, Canaccord Genuity Group, Citigroup, Evercore, Robert W. Baird, Royal Bank Of Canada, TD Cowen, Truist Financial, and Weiss Ratings in the past 90 days.

Analysts like Edwards Lifesciences more than other "medical" companies. The consensus rating for Edwards Lifesciences is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how EW compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Edwards Lifesciences Recommendations

This page (NYSE:EW) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

EW Analyst Ratings Over Time

EW Analyst Recommendations By Month

EW Price Targets by Month

Edwards Lifesciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

Edwards Lifesciences
Bull Case

Edwards Lifesciences
Bear Case

EW Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Edwards Lifesciences Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

EW Analyst Ratings Over Time

EW Analyst Recommendations By Month

EW Price Targets by Month

Edwards Lifesciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

Edwards Lifesciences Bull Case

Edwards Lifesciences Bear Case

EW Forecast - Frequently Asked Questions

What is Edwards Lifesciences' forecast for 2026?

Should I buy or sell Edwards Lifesciences stock right now?

Does Edwards Lifesciences's stock price have much upside?

What analysts cover Edwards Lifesciences?

Do Wall Street analysts like Edwards Lifesciences more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Edwards Lifesciences Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Edwards Lifesciences
Bull Case

Edwards Lifesciences
Bear Case